Nicholas Kennedy
Appearances
- DateMay 7, 2023Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
- DateMay 21, 2024Management strategies and clinical outcomes vary substantially in patients newly-diagnosed with Crohn’s disease…
Presenter
Speakers
Katholieke Universiteit Leuven Universitaire Ziekenhuizen LeuvenWestern UniversityBarts & The London School of Medicine and Dentistry